Other

The Scripps Research Institute

Her Majesty the Queen in Right of Canada, As Represented by the Minister

Emergent Biosolutions Canada Inc.

Jody Berry

Mike Gubbins

Raymond Tsang

Xin Yuan

Cindi Corbett

Amin Kabani

Lisa Schmidt

Steven J Jones

Xin Yong Yuan

Anton Andonov

Hana Weingartl

Mike Drebot

Frank Plummer

Hana Weingarti

The characterization and isolation of F20G75, F20G76 and F20G77, anti-PA monoclonal antibodies which also have neutralizing activities is described. The monoclonal antibodies may be used as a pharmaceutical composition for treating individuals suspected of or at risk of or having ainfection. The monoclonal antibodies bind to a specific region comprising amino acids 311-316 of PA, ASFFDI or a larger fragment comprising amino acids 301-330 of PA, SEVHGNAEVHASFFDIGSSVSAGFSNSNSS. Vaccines comprising these peptides may be used to immunize individuals againstinfection.

Monoclonal antibodies to anthrax protective antigen

Monoclonal antibody reagents that recognize the SARS-coronavirus (SARS-HCoV) are needed urgently. In this report we describe the development and immunochemical characterization of mAbs against the SARS-HCoV based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of seventeen mAbs. Five mAbs exhibited Western immunoblot reactivity with the denatured spike protein, of which two demonstrated the ability to neutralize SARS-HCoV in vitro. Another four Western immunoblot-negative mAbs also neutralize the virus. These antibodies will be useful for the development of diagnostic tests, pathogenicity and vaccine studies.

Anti-SARS monoclonal antibodies

Growing community of inventors

Winnipeg, Canada

Jody Berry